trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'trastuzumab']
much awaited presentation at #asco2022. fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer - the asco post 
Oncologist, researcher and educator, cancer centre head at @PantaiHospKL, cancer doc at Subang Jaya Medical Centre, Secretary @ Malaysian Oncology Society